Âé¶¹´«Ã½Ó³»­

Âé¶¹´«Ã½Ó³»­

Explore the latest content from across our publications

Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

Hyperglycemia as Predictor of In-Hospital Worsening after Acute Ischemic Stroke: The Northern Manhattan Study
Cerebrovascular Disease and Interventional Neurology
(-)
105
Authors/Disclosures
Richard E. Temes, MD (Northwell Health) No disclosure on file
No disclosure on file
Marco A. Arruda, MD, PhD (Glia Institute) No disclosure on file
No disclosure on file
Renato Arruda, MD (Instituto Glia) No disclosure on file
No disclosure on file
Vincenzo Guidetti No disclosure on file
Bernadette Boden-Albala, DrPH (University California Irvine) Ms. Boden-Albala has nothing to disclose.
Marcelo E. Bigal, MD, PhD (Purdue) No disclosure on file
No disclosure on file
Ralph L. Sacco, MD, MS, FAHA Dr. Sacco has received personal compensation in the range of $100,000-$499,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for American Heart Association. The institution of Dr. Sacco has received research support from NIH, NINDS, NCATS, NIMHD. The institution of Dr. Sacco has received research support from FL Department of Health. Dr. Sacco has received research support from University of Washington, Seattle. Dr. Sacco has received publishing royalties from a publication relating to health care.
Keith Van Haren, MD (Stanford Univ Neurology) Dr. Van Haren has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Viking Therapeutics. Dr. Van Haren has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Bluebirdbio. Dr. Van Haren has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Orpheris. Dr. Van Haren has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Autobahn. Dr. Van Haren has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for PRIME, Inc. The institution of Dr. Van Haren has received research support from Minoryx. The institution of Dr. Van Haren has received research support from bluebirdbio. Dr. Van Haren has a non-compensated relationship as a Board of Directors with ALD Connect that is relevant to Âé¶¹´«Ã½Ó³»­ interests or activities. Dr. Van Haren has a non-compensated relationship as a Scientific Advisory Board with United Leukodystrophy Foundation that is relevant to Âé¶¹´«Ã½Ó³»­ interests or activities.